Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

August 6, 2019

‘Off-the-shelf’ CAR T-Cell Therapy Moving Toward 1st Clinical Trial with Takeda

News

A new chimeric antigen receptor (CAR) T-cell therapy derived from induced pluripotent stem cells (iPSCs) has been transferred to Takeda from the Center for iPS Cell Research and Application (CiRA) ... Read more

July 31, 2019September 9, 2019

FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Liver Cancer

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) as a first-line treatment for patients with advanced unresectable ... Read more

July 26, 2019July 26, 2019

NantKwest Launches Phase 1 Trial to Assess Investigational Cell Therapy for Solid Cancers

News

A first-in-human Phase 1 clinical trial has been launched to assess the effects of NantKwest’s investigational PD-L1 t-haNK cell therapy in patients with locally advanced or metastatic solid cancers. The ... Read more

July 19, 2019

Prophylactic anti-TNF Therapy Improves Safety of Immunotherapies, Mouse Study Says

News

Prophylactic anti-TNF therapy improves the safety and, to some degree, the efficacy of checkpoint blockade combination immunotherapies, a mouse study says. The findings of the study, “Prophylactic TNF blockade uncouples ... Read more

July 16, 2019

FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule

News

The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can ... Read more

June 25, 2019June 25, 2019

Keytruda Found to be Safe as Cancer Treatment for HIV Patients, Phase 1 Trial Shows

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) was found to be a safe treatment for different cancer types among people living with HIV, data from a Phase 1 trial show. The results are ... Read more

June 11, 2019

Keytruda Improves Survival of Patients with Recurrent or Metastatic Head, Neck Cancer, Phase 3 Trial Shows

News

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care treatment, ... Read more

June 5, 2019

Kite’s Investigational CAR-T Cell Therapy Shows Promise in Phase 1/2 Trial

News

A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 trial ... Read more

April 24, 2019

Aprea’s APR-246 Stabilizes Key Tumor Suppressor Protein and Boosts Immune Responses in Mouse Study

News

Aprea Therapeutics‘ APR-246 stabilizes the tumor suppressor protein p53, boosting responses to checkpoint blockade immunotherapies in mouse models of melanoma and colorectal cancer, a study says. Findings were announced in ... Read more

April 23, 2019

Melanomas with NF-kB Activation Are Easier to Target with Immune Checkpoint Inhibitors, Study Says

News

Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about three ... Read more